From branded generics to drugs developed specifically for patients in Asia, Bethan Hughes investigates the strategies that large-cap pharmaceutical companies are pursuing to meet the medical needs of emerging markets.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Obstacles and opportunities in Chinese pharmaceutical innovation
Globalization and Health Open Access 24 March 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Evolving R&D for emerging markets. Nat Rev Drug Discov 9, 417–420 (2010). https://doi.org/10.1038/nrd3204
Issue Date:
DOI: https://doi.org/10.1038/nrd3204
This article is cited by
-
Obstacles and opportunities in Chinese pharmaceutical innovation
Globalization and Health (2017)
-
Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration
Acta Pharmacologica Sinica (2016)
-
Ethnic-Specific In Vitro–In Vivo Extrapolation and Physiologically Based Pharmacokinetic Approaches to Predict Cytochrome P450-Mediated Pharmacokinetics in the Chinese Population: Opportunities and Challenges
Clinical Pharmacokinetics (2014)
-
News in brief
Nature Reviews Drug Discovery (2010)
-
China spurs pharma innovation
Nature Reviews Drug Discovery (2010)